文章名稱引用次數

• Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis69
• Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR67
• Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX60
• Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial43
• The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis40
• Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up33
• Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in he United States29
• Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-228
• From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives28
• Thrombopoietin receptor agonists: ten years later27